This article and associated images are based on a poster originally authored by Denise Sullivan, Zhong Yu, Benjamin Streeter, Stacie Chvatal and Daniel Millard and presented at ELRIG Drug Discovery ...

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed ...

Serplulimab achieves pharmacodynamic saturation, supporting its current clinical use without the need for higher doses. The ASTRUM-005 trial established serplulimab as the PD-1 inhibitor with the ...

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease 15 ...

Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not ...

3 Faculty of Sports Sciences, Universidad Europea de Madrid, Madrid, Spain 4 Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain 5 Department of Sports Science and ...

A lower-than-recommended dose of edoxaban (Savaysa; Daiichi Sankyo) lessens bleeding without compromising protection against ischemic events in elderly patients with atrial fibrillation (AF), a post ...